Press Release
« Back
TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 51st Annual Meeting of the American Society of Clinical Oncology
May 13, 2015
The Triple-Combination Therapy of TG-1101, TGR-1202, and ibrutinib to be Highlighted in an Oral Presentation
Updates on the Combination of TG-1101 Plus TGR-1202, and Single-Agent TGR-1202 to be Featured in Poster Presentations
The presentation schedule at ASCO 2015 is as follows:
Oral Presentation:
-
Title: Safety and activity of the chemotherapy-free triplet of ublituximab, TGR-1202, and ibrutinib in relapsed B-cell malignancies
- Abstract Number: 8501
-
Presentation Date & Time:
Monday, June 1, 2015 ,9:57AM -10:09AM CT - Session Type/Track: Oral Abstract Session/ Lymphoma and Plasma Cell Disorders
-
Presenter:
Nathan H. Fowler , MD, University of Texas MD Anderson Cancer Center
Poster Presentations:
-
Title: Ublituximab plus TGR-1202 activity and safety profile in relapsed/refractory B-cell
NHL and high-risk CLL- Abstract Number: 8548
-
Presentation Date & Time:
Sunday, May 31, 2015 ,8:00AM -11:30AM CT - Track: Lymphoma and Plasma Cell Disorders
-
Presenter:
Matthew A. Lunning , DO,University of Nebraska Medical Center
-
Title: Clinical activity and safety profile of TGR-1202, a novel once daily PI3K delta inhibitor, in patients with CLL and B-cell lymphoma
- Abstract Number: 7069
-
Presentation Date & Time:
Sunday, May 31, 2015 ,8:00AM -11:30AM CT - Track: Leukemia, Myelodysplasia, and Transplantation
-
Presenter:
Howard A. Burris , MD,Sarah Cannon Research Institute ,Tennessee Oncology, PLLC
A copy of the ASCO abstracts were made available today,
ABOUT
Cautionary Statement
Some of the statements included in this press release, particularly those with respect to anticipating future clinical trials, the timing of commencing or completing such trials and business prospects for TG-1101, TGR-1202, the IRAK4 inhibitor program, and the anti-PD-L1 and anti-GITR antibodies may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete pre-clinical and clinical trials for TG-1101, TGR-1202, the IRAK4 inhibitor program and the anti-PD-L1 and anti-GITR antibodies; the risk that early pre-clinical and clinical results that supported our
decision to move forward with TG-1101, TGR-1202, the IRAK4 inhibitor program and the anti-PD-L1 and anti-GITR antibodies will not be reproduced in additional patients or in future studies; the risk that trends observed which underlie certain assumptions of future performance of TGR-1202 will not continue, the risk that TGR-1202 will not produce satisfactory safety and efficacy results to warrant further development following the completion of the current Phase 1 study; the risk that the data (both safety and efficacy) from future clinical trials will not coincide with the data produced from prior pre-clinical and clinical trials; the risk that trials will take longer to enroll than expected; our ability to achieve the milestones we project over the next year; our ability to manage our cash in line with our projections, and other risk factors identified from time to time in our reports
filed with the
TGTX - G
CONTACT:Source:Jenna Bosco Director- Investor RelationsTG Therapeutics, Inc. Telephone: 212.554.4351 Email: ir@tgtxinc.com
News Provided by Acquire Media